Arek Dudek, PhD, MD

Arek Dudek, PhD, MD

Chief Medical Officer

Dr. Dudek practicing specialty is Oncology and Hematology. He has been published more than 100 times in peer-reviewed medical journals for his work in lung cancer, melanoma and kidney cancer. Served as site PI for:

  • Conducted Phase Ib and Phase II Studies of anti-PD-1 Antibody MK-3475 in Combination with Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003
  • Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma: HCRN LUN15-299
  • A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma
  • Anti-programmed Death – Ligand 1 Antibody, MEDI4736, in Combination with Chemotherapy for the First Line Treatment of Unresectable Mesothelioma
  • A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
  • An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-Nephrectomy Followed by Sunitinib Post-Nephrectomy, Compared to Sunitinib Post-Nephrectomy in Metastatic Renal Cell Carcinoma Patients
  • Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors
  • Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination with Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors